Abstract
The therapy of inflammatory bowel disease is represents a challenge in current gastroenterology. Progressive research brings us new promising molecules and our growing clinical experience leads us to create new therapeutic strategies.
New multi-matrix formulas of corticosteroids or 5-ASA start to be widely used in clinical practice along with new biological therapy. Biosimilars are making biological therapy more accessible for patients.
Evaluation of new possible treatment modalities (i.e. faecal bacteriotherapy) is an objective of ongoing studies.